Osteoporosis in Rheumatic Diseases

Anti-rheumatic Drugs and the Skeleton

Alanna M. Dubrovsky, Mie Jin Lim, Nancy E Lane

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Osteoporosis in rheumatic diseases is a very well-known complication. Systemic inflammation results in both generalized and localized bone loss and erosions. Recently, increased knowledge of inflammatory process in rheumatic diseases has resulted in the development of potent inhibitors of the cytokines, the biologic DMARDs. These treatments reduce systemic inflammation and have some effect on the generalized and localized bone loss. Progression of bone erosion was slowed by TNF, IL-6 and IL-1 inhibitors, a JAK inhibitor, a CTLA4 agonist, and rituximab. Effects on bone mineral density varied between the biological DMARDs. Medications that are approved for the treatment of osteoporosis have been evaluated to prevent bone loss in rheumatic disease patients, including denosumab, cathepsin K, bisphosphonates, anti-sclerostin antibodies and parathyroid hormone (hPTH 1–34), and have some efficacy in both the prevention of systemic bone loss and reducing localized bone erosions. This article reviews the effects of biologic DMARDs on bone mass and erosions in patients with rheumatic diseases and trials of anti-osteoporotic medications in animal models and patients with rheumatic diseases.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalCalcified Tissue International
DOIs
StateAccepted/In press - Feb 22 2018

Fingerprint

Antirheumatic Agents
Rheumatic Diseases
Skeleton
Osteoporosis
Bone and Bones
Cathepsin K
Inflammation
Diphosphonates
Parathyroid Hormone
Interleukin-1
Bone Density
Anti-Idiotypic Antibodies
Interleukin-6
Animal Models
Cytokines
Therapeutics

Keywords

  • Ankylosing spondylitis
  • Anti-osteoporotic medication
  • Anti-rheumatic drug
  • Bone loss
  • Osteoporosis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

Osteoporosis in Rheumatic Diseases : Anti-rheumatic Drugs and the Skeleton. / Dubrovsky, Alanna M.; Lim, Mie Jin; Lane, Nancy E.

In: Calcified Tissue International, 22.02.2018, p. 1-12.

Research output: Contribution to journalArticle

@article{742250a0d87b4a288d759a7c9805a214,
title = "Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton",
abstract = "Osteoporosis in rheumatic diseases is a very well-known complication. Systemic inflammation results in both generalized and localized bone loss and erosions. Recently, increased knowledge of inflammatory process in rheumatic diseases has resulted in the development of potent inhibitors of the cytokines, the biologic DMARDs. These treatments reduce systemic inflammation and have some effect on the generalized and localized bone loss. Progression of bone erosion was slowed by TNF, IL-6 and IL-1 inhibitors, a JAK inhibitor, a CTLA4 agonist, and rituximab. Effects on bone mineral density varied between the biological DMARDs. Medications that are approved for the treatment of osteoporosis have been evaluated to prevent bone loss in rheumatic disease patients, including denosumab, cathepsin K, bisphosphonates, anti-sclerostin antibodies and parathyroid hormone (hPTH 1–34), and have some efficacy in both the prevention of systemic bone loss and reducing localized bone erosions. This article reviews the effects of biologic DMARDs on bone mass and erosions in patients with rheumatic diseases and trials of anti-osteoporotic medications in animal models and patients with rheumatic diseases.",
keywords = "Ankylosing spondylitis, Anti-osteoporotic medication, Anti-rheumatic drug, Bone loss, Osteoporosis, Rheumatoid arthritis",
author = "Dubrovsky, {Alanna M.} and Lim, {Mie Jin} and Lane, {Nancy E}",
year = "2018",
month = "2",
day = "22",
doi = "10.1007/s00223-018-0401-9",
language = "English (US)",
pages = "1--12",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",

}

TY - JOUR

T1 - Osteoporosis in Rheumatic Diseases

T2 - Anti-rheumatic Drugs and the Skeleton

AU - Dubrovsky, Alanna M.

AU - Lim, Mie Jin

AU - Lane, Nancy E

PY - 2018/2/22

Y1 - 2018/2/22

N2 - Osteoporosis in rheumatic diseases is a very well-known complication. Systemic inflammation results in both generalized and localized bone loss and erosions. Recently, increased knowledge of inflammatory process in rheumatic diseases has resulted in the development of potent inhibitors of the cytokines, the biologic DMARDs. These treatments reduce systemic inflammation and have some effect on the generalized and localized bone loss. Progression of bone erosion was slowed by TNF, IL-6 and IL-1 inhibitors, a JAK inhibitor, a CTLA4 agonist, and rituximab. Effects on bone mineral density varied between the biological DMARDs. Medications that are approved for the treatment of osteoporosis have been evaluated to prevent bone loss in rheumatic disease patients, including denosumab, cathepsin K, bisphosphonates, anti-sclerostin antibodies and parathyroid hormone (hPTH 1–34), and have some efficacy in both the prevention of systemic bone loss and reducing localized bone erosions. This article reviews the effects of biologic DMARDs on bone mass and erosions in patients with rheumatic diseases and trials of anti-osteoporotic medications in animal models and patients with rheumatic diseases.

AB - Osteoporosis in rheumatic diseases is a very well-known complication. Systemic inflammation results in both generalized and localized bone loss and erosions. Recently, increased knowledge of inflammatory process in rheumatic diseases has resulted in the development of potent inhibitors of the cytokines, the biologic DMARDs. These treatments reduce systemic inflammation and have some effect on the generalized and localized bone loss. Progression of bone erosion was slowed by TNF, IL-6 and IL-1 inhibitors, a JAK inhibitor, a CTLA4 agonist, and rituximab. Effects on bone mineral density varied between the biological DMARDs. Medications that are approved for the treatment of osteoporosis have been evaluated to prevent bone loss in rheumatic disease patients, including denosumab, cathepsin K, bisphosphonates, anti-sclerostin antibodies and parathyroid hormone (hPTH 1–34), and have some efficacy in both the prevention of systemic bone loss and reducing localized bone erosions. This article reviews the effects of biologic DMARDs on bone mass and erosions in patients with rheumatic diseases and trials of anti-osteoporotic medications in animal models and patients with rheumatic diseases.

KW - Ankylosing spondylitis

KW - Anti-osteoporotic medication

KW - Anti-rheumatic drug

KW - Bone loss

KW - Osteoporosis

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85042373593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042373593&partnerID=8YFLogxK

U2 - 10.1007/s00223-018-0401-9

DO - 10.1007/s00223-018-0401-9

M3 - Article

SP - 1

EP - 12

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

ER -